Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. (Q38079915)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

1 reference

Francis E. Marchlinski

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Tahmeed Contractor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Vadim Levin

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Matthew W Martinez

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

1 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

published in

Postgraduate Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

34-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Validation of Clinical Classification Schemes for Predicting Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Drug-induced liver injury in humans: the case of ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Drug and dietary interactions of the new and emerging oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Challenges for providing effective hemostasis in surgery and trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Apixaban in Patients with Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Reversal of antithrombotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Prothrombin complex concentrates: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.01.2622

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.01.2622

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23391669%20AND%20SRC:MED&resulttype=core&format=json